Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, aripiprazole (Abilify®) cannot be endorsed for use within NHS Wales for the rapid control of agitation and disturbed behaviours in patients with schizophrenia or in patients with manic episodes in Bipolar I Disorder, when oral therapy is not appropriate. |
||
|
||
Medicine details |
||
| Medicine name | aripiprazole (Abilify®) | |
| Formulation | 7.5 mg/ml solution for injection | |
| Reference number | 26 | |
| Indication | For the rapid control of agitation and disturbed behaviours in patients with schizophrenia or in patients with manic episodes in Bipolar I Disorder, when oral therapy is not appropriate. |
|
| Company | Otsuka Pharmaceutical (UK) Ltd | |
| BNF chapter | Central nervous system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 10/02/2009 | |